Ce qui a changé
Ce qui a changéEntre le 14 septembre et le 29 septembre 2026, Eli Lilly a mené plusieurs essais cliniques, incluant des études sur de nouveaux composés et l'achèvement d'un essai de phase 4 pour un traitement contre le diabète. Ces activités visent à évaluer le potentiel thérapeutique d'agents expérimentaux et de nouvelles indications pour des médicaments existants.

Historique de la société
Octobre 2026
ELI LILLY & Co: 12 recorded developments from 7 official sources in 2026-10.
- 2026-10-08: Participants receive eloralintide subcutaneously as the experimental intervention. Source
- 2026-10-08: Participants receive single doses of LY4268989 in six treatment arms, with high‑fat and fasted states. Source
- 2026-10-08: The study enrolls 123 healthy participants and includes four inpatient stays at the clinical research unit. Source
- 2026-10-08: The study has four parts: single-ascending dose, multiple-ascending dose, single dose in three periods, and midazolam co‑administration. Source
- 2026-10-08: The trial is recruiting participants with overweight or prediabetic conditions to receive the investigational drug Orforglipron orally. Source
- 2026-10-08: Participants will receive LY4329090 administered subcutaneously (SC). Source
- 2026-10-08: The study includes two parts: Part A lasting about 10 weeks with 5 nights stay and 5 outpatient visits, Part B lasting about 21 weeks with 4 stays totaling 11 nights and 14 outpatient visits. Source
- 2026-10-08: The study is a randomized, parallel, double‑masked, basic science interventional study with estimated enrollment of 184 participants. Source
- 2026-10-08: The study will enroll 161 participants and is a Phase 2 randomized, open-label, parallel-design intervention study. Source
- 2026-10-08: The study will evaluate vepugratinib in adults with low‑grade, intermediate‑risk non‑muscle invasive bladder cancer or low‑grade upper tract urothelial carcinoma. Source
- 2026-10-09: The primary purpose of the study is basic science evaluating the safety and tolerability of LY5625575. Source
- 2026-10-09: The study will include healthy participants and participants with elevated high-sensitivity C-reactive protein. Source
Septembre 2026
ELI LILLY & Co: 12 recorded developments from 7 official sources in 2026-09.
- 2026-09-23: The intervention includes abemaciclib in three formulations: Tablet Test Formulation 1, Oral Granules Test Formulation 2, and Reference Tablet Formulation 1. Source
- 2026-09-23: The trial will last about 8 weeks, including screening and follow-up. Source
- 2026-09-24: The trial is a phase 2, nonrandomized, sequential, open-label, single‑arm study of mosunetuzumab plus pirtobrutinib in relapsed or refractory Waldenstrom’s Macroglobulinemia. Source
- 2026-09-24: Patients must be ≥18 years with measurable Waldenstrom’s Macroglobulinemia and have relapsed or refractory disease after at least one prior line of therapy. Source
- 2026-09-24: The total number of cycles administered is 18 for patients with a complete, very good partial or minor response in dosing strategy 1 and 19 in dosing strategy 2. Source
- 2026-09-28: The trial is a prospective, single-arm, nonrandomized, open-label, phase I/II study of abemaciclib and endocrine therapy with stereotactic radiosurgery (SRS) in patients with hormone receptor (HR)+/HER2- metastatic breast cancer brain metastases. Source
- 2026-09-28: Treatment will be initiated with one week of abemaciclib followed by stereotactic radiation to sites of brain metastases or post-operative cavities with continued abemaciclib. Source
- 2026-09-28: The trial intervention included subcutaneous injections of insulin lispro-aabc (also known as LY900014 or Lyumjev) combined with insulin glargine (Basaglar). Source
- 2026-09-28: The company's product, baricitinib (Olumiant), was evaluated in a Phase 2 study for the treatment of central centrifugal cicatricial alopecia in adults of African descent. Source
- 2026-09-28: In a Phase 2 trial of baricitinib for central centrifugal cicatricial alopecia, 27 participants received at least one dose and 17 completed the 52-week treatment period. Source
- 2026-09-29: Eli Lilly and Company is conducting a Phase 1 study to evaluate the tolerability and side effects of the drug LY4057996 in healthy participants and those with Type 1 or Type 2 Diabetes. Source
- 2026-09-29: The study arms include experimental groups testing LY4057996 administered subcutaneously or intravenously, alone or in combination with other agents such as Lispro and basal insulin, against placebo and active comparators. Source
Les synthèses mensuelles sont rédigées par l’IA à partir des rapports et sources officielles vérifiés de chaque mois (en anglais, tels qu’extraits), chaque ligne renvoyant à sa source ; les fils conducteurs regroupent les développements liés entre analyses grâce aux embeddings vectoriels (Amazon Titan Text Embeddings V2). Contexte provisoire, pas un conseil en investissement.
Pairs du secteur
Comparaison avec 36 entreprises suivies dans le secteur Santé (variation médiane du CA : +7,2% sur 1 an), d'après les données SEC XBRL.
| Entreprise | Dernier CA | CA sur 1 an | Marge opérationnelle |
|---|
| ELI Lilly & Co LLY | 24,4 Md $ | +38,6% | — |
| Unitedhealth Group Inc UNH | 113 Md $ | -0,4% | 5,8% |
| Mckesson Corp MCK | 111 Md $ | +7,6% | 1,4% |
| CVS Health Corp CVS | 108 Md $ | +5,4% | 3,3% |
| Cigna Group CI | 73,7 Md $ | +5,6% | 3,3% |
| Cardinal Health Inc CAH | 67,5 Md $ | +5,5% | 1,1% |
| Elevance Health, Inc. ELV | 51,4 Md $ | +1,4% | 2,5% |
Dernière période publiée par entreprise selon SEC CompanyFacts (XBRL). Les calendriers fiscaux peuvent différer.
Grands fonds (13F)
| Fonds | Actions | Valeur | Variation du nombre d’actions | Trimestre |
|---|
| BlackRock | 67 936 153 | $78 607 563 355 | +0,6% | T3 2026 |
| State Street | 36 848 565 | $42 636 737 590 | +1,7% | T3 2026 |
| Fidelity (FMR) | 29 959 147 | $34 665 130 320 | +5,3% | T3 2026 |
| Geode Capital Management | 20 556 572 | $23 722 722 425 | +1,2% | T3 2026 |
| Capital Research Global Investors | 16 998 595 | $19 670 092 948 | -18,6% | T3 2026 |
| Norges Bank (Norway's sovereign fund) | 11 471 413 | $13 759 156 895 | — | T2 2026 |
| Wellington Management | 11 048 493 | $12 783 990 282 | +0,5% | T3 2026 |
| Citadel Advisors | 681 483 | $788 530 350 | -27,9% | T3 2026 |
| Two Sigma Investments | 339 220 | $392 504 678 | +317,6% | T3 2026 |
| D. E. Shaw & Co. | 316 379 | $366 075 814 | -36,3% | T3 2026 |
| Millennium Management | 199 938 | $231 344 261 | +9,4% | T3 2026 |
| ARK Investment Management (Cathie Wood) | 107 838 | $124 776 742 | +39,6% | T3 2026 |
| Bridgewater Associates | 94 722 | $109 600 932 | +8,8% | T3 2026 |
| Soros Fund Management | 22 199 | $25 686 019 | 0,0% | T3 2026 |
| T. Rowe Price | 13 383 370 | $15 485 631 | -3,8% | T3 2026 |
D’après les rapports trimestriels 13F-HR des grands fonds que nous suivons, tels que déposés. Les fonds déclarent jusqu’à 45 jours après la fin du trimestre : les positions ont pu changer depuis. Variation : par rapport au trimestre précédent du même fonds. Pas une recommandation.